Neo‐PATH, a single‐arm, nonrandomized trial, investigated preoperative atezolizumab combined with docetaxel, trastuzumab, and pertuzumab in stage II or III HER2‐positive breast cancer patients. Here, ERBB2 is linked to breast carcinoma.